What is Global Diagnostic Nuclear Medicines Market?
The Global Diagnostic Nuclear Medicines Market is a rapidly expanding sector within the healthcare industry. It involves the use of radioactive substances, known as radiopharmaceuticals, for the diagnosis and treatment of various diseases. These radiopharmaceuticals are introduced into the body, usually by injection, and their radiation emissions are then detected and analyzed to provide detailed images of the inside of the body. This allows doctors to diagnose conditions such as cancer, heart disease, and neurological disorders with a high degree of accuracy. The market for these diagnostic nuclear medicines was valued at a substantial US$ 4722 million in 2023 and is projected to grow to an impressive US$ 7534.8 million by 2030. This represents a compound annual growth rate (CAGR) of 6.9% during the forecast period from 2024 to 2030.
Tc-99m, F-18, Other in the Global Diagnostic Nuclear Medicines Market:
Tc-99m, F-18, and other radiopharmaceuticals are key components of the Global Diagnostic Nuclear Medicines Market. Tc-99m, or Technetium-99m, is the most commonly used radioactive tracer in nuclear medicine. It is used in a wide range of diagnostic tests, including scans of the brain, heart, lungs, and bones. F-18, or Fluorine-18, is another important radioactive tracer. It is used primarily in positron emission tomography (PET) scans, which provide detailed images of the body's metabolic activity. Other radiopharmaceuticals used in diagnostic nuclear medicine include Iodine-131, Thallium-201, and Gallium-67. Each of these radioactive tracers has its own unique properties and uses, making them invaluable tools in the diagnosis and treatment of a wide range of diseases.
Oncology, Cardiology, Other in the Global Diagnostic Nuclear Medicines Market:
The Global Diagnostic Nuclear Medicines Market plays a crucial role in several key areas of healthcare, including oncology, cardiology, and others. In oncology, diagnostic nuclear medicines are used to detect and monitor the progression of various types of cancer. They can provide detailed images of tumors, allowing doctors to determine the size, location, and metabolic activity of the cancer. In cardiology, these medicines are used to assess the health of the heart. They can provide images of the heart's structure and function, helping doctors to diagnose conditions such as coronary artery disease and heart failure. Other areas where diagnostic nuclear medicines are used include neurology, where they can help to diagnose conditions such as Alzheimer's disease and Parkinson's disease, and endocrinology, where they can be used to investigate thyroid disorders.
Global Diagnostic Nuclear Medicines Market Outlook:
The future of the Global Diagnostic Nuclear Medicines Market looks promising, with a projected growth from US$ 4722 million in 2023 to US$ 7534.8 million by 2030. This represents a compound annual growth rate (CAGR) of 6.9% during the forecast period from 2024 to 2030. This growth is driven by the increasing prevalence of chronic diseases such as cancer and heart disease, as well as the ongoing advancements in nuclear medicine technology. These advancements are making diagnostic nuclear medicines more effective and accessible, thereby driving their increased use in healthcare settings around the world.
| Report Metric | Details |
| Report Name | Diagnostic Nuclear Medicines Market |
| Accounted market size in 2023 | US$ 4722 million |
| Forecasted market size in 2030 | US$ 7534.8 million |
| CAGR | 6.9% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Pharma, Bracco Imaging, Novartis, SIEMENS, China Isotope & Radiation, Dongcheng, Lantheus, Eli Lilly |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
